---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-037470"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:16:26.176206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt

## Summary
- Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.
- Net loss $3.19M vs $1.77M in 2024; G&A rose to $5.5M from $1.5M on public listing costs.
- Phase 2 trial of GX-03 for atopic dermatitis on track; topline results expected mid-2026.
- Appointed former CDC Director Dr. Robert Redfield and Martin Dewhurst (ex-McKinsey) to leadership/board.
- Entered global license, supply, and distribution agreement with Medline; revenue expected to begin late 2026.

## SEC filing metadata
- accession: 0001213900-26-037470
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/0001213900-26-037470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/ea0283795-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-037470
- JSON: https://secwatch.observer/filing/0001213900-26-037470.json
- Plain text: https://secwatch.observer/filing/0001213900-26-037470.txt

## Key facts
- Earnings Releases
  Turn Therapeutics Inc. reported the year ended December 31, 2025 results: net income NET LOSS $ (3,194,080 ), EPS Basic and diluted net loss per common share $ (0.12 ).
  - Period: the year ended December 31, 2025
  - Net income: NET LOSS $ (3,194,080 )
  - EPS: Basic and diluted net loss per common share $ (0.12 )
  - Result: reported results
  source text: liability 380,442 - Amortization of deferred offering cost (496,948 ) - Interest income 29,583 28,709 Other income 176,520 - Total other income 2,664,568 28,709 NET LOSS $ (3,194,080 ) $ (1,768,415 ) Basic and diluted net loss per common share $ (0.12 ) $ (0.07 ) Weighted-average common shares outstanding, basic and diluted 27,716,045 26,643,432 Turn
  evidence_url: https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/0001213900-26-037470-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.